However, these discrepancies likely reflect differences in trial design, patient selection criteria—such as the number of patients randomized with upper tract urothelial carcinoma—and the pharmacodynamics of PD-1 versus PD-L1 inhibitors. This evidence concerns the gene CD274 and renal pelvis/ureter urothelial carcinoma.